JY
TNGX icon

Jeff Yass’s Tango Therapeutics TNGX Stock Holding History

Jeff Yass’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.94M Buy
93,900
+60,500
+181% +$1.5M ﹤0.01% 5675
2026
Q1 		$699K Buy
+33,400
New +$465K ﹤0.01% 8816
2025
Q4 		– Sell
-14,300
Closed -$120K – 13631
2025
Q3 		$120K Buy
+14,300
New +$96.8K ﹤0.01% 11449

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Jeff Yass's TNGX Position: Q2 2026 in Review

Jeff Yass increased its Tango Therapeutics (TNGX) stake by 23% in Q2 2026, buying an estimated $485K and bringing the position to 105,985 shares worth $3.31M. The position accounts for ﹤0.01% of the portfolio, ranked #5421.

Jeff Yass first reported a position in TNGX in Q4 2021 and has held it in 17 quarters since. 246 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Jeff Yass held 105,985 shares of Tango Therapeutics worth $3.31M as of Q2 2026.
  • Jeff Yass bought 19,635 Tango Therapeutics shares in Q2 2026, an estimated $485K.
  • Tango Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5421 holding.
  • Jeff Yass first reported a position in Tango Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • 246 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.